GPC3 and hepatocellular carcinoma: A preclinical study focusing on glypican-3 (GPC3) CAR T cell therapy in patients with hepatocellular carcinoma demonstrated survival rates of 50%, 42%, and 10% at 6 months, 1 year, and 3 years, respectively [46].